<DOC>
	<DOCNO>NCT00697762</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety adjunctive RWJ-333369 dose 200 400 mg/day comparison placebo Korean Japanese partial epilepsy patient poor seizure control one two antiepileptic ( AEDs ) .</brief_summary>
	<brief_title>Effectiveness Safety Study RWJ-333369 Adjunctive Therapy Korean Japanese Patients With Partial Onset Seizures</brief_title>
	<detailed_description>Despite introduction new antiepileptic drug overseas clinical setting 1990 's , still exist patient control seizures , thus advent new antiepileptic drug desire . This multicenter , placebo-controlled , double-blind ( neither study physician patient know name study assign medication ) , randomize ( study drug assign chance ) , parallel-group study . It consist three period : Pretreatment Phase ( screen baseline period ) , Double-Blind Treatment Phase , Posttreatment Phase ( transitional period dose-tapering/withdrawal period ) . Patients complete Double-Blind Treatment Phase qualify participate long-term extension study ( Study 333369-KJ-03 ) follow present study . The primary hypothesis 400mg/day RWJ-333369 effective adjunctive treatment patient partial onset epilepsy , measure percent reduction baseline monthly seizure frequency partial onset seizure . Safety evaluate base follow variable ; Adverse event , Lab test , Electrocardiogram , Vital sign , Pregnancy test , Physician Withdrawal Checklist . Patients receive assign dose ( placebo , 200 mg/day , 400 mg/day ) twice daily orally 12 week ( 85 day )</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<criteria>Body weight 40 kg Established diagnosis partial epilepsy least 1 year Current treatment least one two antiepileptic ( AEDs ) At least 6 episode simple partial motor seizure , complex partial seizure , secondarily generalize seizures 2 month ( 56 day ) baseline period ( No seizure free interval 3 week ) Diagnosis status epilepticus epilepsia partialis continuum within 6 month Patients generalize epileptic syndrome Current previous history nonepileptic seizure , include psychogenic seizure Current previous history serious medically relevant systemic disease , include clinically apparent hepatic disease , renal failure , malignant neoplasm , insulinrequiring diabetes mellitus , disorder Patients clinical evidence significant cardiac disease Current past ( within 1 year ) major significant psychotic disorder Have ALT ( GPT ) great 1.5 time upper reference limit total bilirubin upper reference limit screen laboratory test</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Partial onset seizure</keyword>
	<keyword>Adjunctive therapy</keyword>
</DOC>